Background Chronic obstructive pulmonary disease (COPD) often coexists with
cardiovascular disease. Treatments for airflow limitation might improve survival and both …

Chronic obstructive pulmonary disease (COPD) often coexists with other chronic diseases
and comorbidities that can markedly influence patients' health status and prognosis. This is …

Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …

Rationale: The IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease
Treatment) trial demonstrated a significant reduction in all-cause mortality (ACM) risk with …

Background Evidence for the management of chronic obstructive pulmonary disease
(COPD) comes from closely monitored efficacy trials involving groups of patients who were …

Objectives: To determine the effect of long term inhaled corticosteroids on lung function,
exacerbations, and health status in patients with moderate to severe chronic obstructive …

Rationale: Chronic obstructive pulmonary disease (COPD) is characterized by an
accelerated decline in lung function. No drug has been shown conclusively to reduce this …

BACKGROUND: Once-daily combination treatment is an attractive maintenance therapy for
COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is …

BACKGROUND: Fluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled
corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess …

The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …